Mp52-13 Retrospective Concomitant Nonrandomized Comparison of Testosterone Replacement Therapy Versus No Treatment for Erectile Function Post Radical Prostatectomy

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy II (MP52)1 May 2024MP52-13 RETROSPECTIVE CONCOMITANT NONRANDOMIZED COMPARISON OF TESTOSTERONE REPLACEMENT THERAPY VERSUS NO TREATMENT FOR ERECTILE FUNCTION POST RADICAL PROSTATECTOMY Muhammed Alaa Moukhtar Hammad, Rafael Gevorkyan, Joshua Tran, Catherine Fung, David W. Barham, Thomas E. Ahlering, and Faysal A. Yafi Muhammed Alaa Moukhtar HammadMuhammed Alaa Moukhtar Hammad , Rafael GevorkyanRafael Gevorkyan , Joshua TranJoshua Tran , Catherine FungCatherine Fung , David W. BarhamDavid W. Barham , Thomas E. AhleringThomas E. Ahlering , and Faysal A. YafiFaysal A. Yafi View All Author Informationhttps://doi.org/10.1097/01.JU.0001008864.84854.b7.13AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recent studies have shown that testosterone replacement therapy (TRT) can be safely applied in men with low-risk prostate cancer. Our aim is to assess TRT versus no TRT 2-year potency outcomes in hypogonadal men aged ≥60. METHODS: Retrospective concomitant nonrandomized comparison of 70 hypogonadal men, aged 60 or older, were stratified by TRT post-RP. Baseline demographics, total testosterone (TT) calculated free testosterone (cFT), and comorbidities prior to RP were measured from October 2016 – October 2020. Sexual function was assessed via the International Index of Erectile Function (IIEF-5) pre-and post-surgery. Potency (evaluated at 3-, 9-, 15-, and 24-months post-RP) was defined as erections sufficient for penetration and satisfying, and/or erection fullness >75%, and/or a score of 5 on Q1 (IIEF-5; confidence). T-tests, chi-square, and regression analyses were performed. RESULTS: Potency at 2 years was 63.6% (TRT) versus 35.1% (No TRT; p=0.017). Regression analysis showed that TRT was a predictor of potency outcomes 2 years post-RP (OR: 3.33; 95% CI: 1.16- 10.3; p=0.029) after adjusting for age and Gleason Grade Group. There were no statistically significant differences in baseline factors between the TRT-receiving and no-TRT groups. BCR rates between the two groups were 12.1% (TRT) versus 27.0% (no TRT; p=0.12) with a mean follow-up time of 40.2±13.6 months. Kaplan Meier analysis demonstrated a trend toward a significant difference in time to BCR (p=0.078). CONCLUSIONS: In hypogonadal men aged ≥60, TRT displayed improved potency in patients 2-years post-RP. The risk of BCR overall in men receiving TRT was lower but not statistically significant. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e857 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Muhammed Alaa Moukhtar Hammad More articles by this author Rafael Gevorkyan More articles by this author Joshua Tran More articles by this author Catherine Fung More articles by this author David W. Barham More articles by this author Thomas E. Ahlering More articles by this author Faysal A. Yafi More articles by this author Expand All Advertisement PDF downloadLoading ...